These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

302 related items for PubMed ID: 1699088

  • 1. Increased anticoagulation during cardiopulmonary bypass by aprotinin.
    de Smet AA, Joen MC, van Oeveren W, Roozendaal KJ, Harder MP, Eijsman L, Wildevuur CR.
    J Thorac Cardiovasc Surg; 1990 Oct; 100(4):520-7. PubMed ID: 1699088
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Aprotinin protects platelets against the initial effect of cardiopulmonary bypass.
    van Oeveren W, Harder MP, Roozendaal KJ, Eijsman L, Wildevuur CR.
    J Thorac Cardiovasc Surg; 1990 May; 99(5):788-96; discussion 796-7. PubMed ID: 1691806
    [Abstract] [Full Text] [Related]

  • 4. A prospective, randomized study of the effects of prostacyclin on platelets and blood loss during coronary bypass operations.
    Fish KJ, Sarnquist FH, van Steennis C, Mitchell RS, Hilberman M, Jamieson SW, Linet OI, Miller DC.
    J Thorac Cardiovasc Surg; 1986 Mar; 91(3):436-42. PubMed ID: 3512919
    [Abstract] [Full Text] [Related]

  • 5. Activated clotting time, anticoagulation, use of heparin, and thrombin activation during extracorporeal circulation: changes under aprotinin therapy.
    Feindt P, Volkmer I, Seyfert U, Huwer H, Kalweit G, Gams E.
    Thorac Cardiovasc Surg; 1993 Feb; 41(1):9-15. PubMed ID: 7690165
    [Abstract] [Full Text] [Related]

  • 6. Aprotinin and heparin monitoring during cardiopulmonary bypass.
    Hunt BJ, Segal H, Yacoub M.
    Circulation; 1992 Nov; 86(5 Suppl):II410-2. PubMed ID: 1385011
    [Abstract] [Full Text] [Related]

  • 7. Heparin dosing and monitoring for cardiopulmonary bypass. A comparison of techniques with measurement of subclinical plasma coagulation.
    Gravlee GP, Haddon WS, Rothberger HK, Mills SA, Rogers AT, Bean VE, Buss DH, Prough DS, Cordell AR.
    J Thorac Cardiovasc Surg; 1990 Mar; 99(3):518-27. PubMed ID: 2308370
    [Abstract] [Full Text] [Related]

  • 8. Heparin resistance and increased platelet activation in coronary surgery patients treated with enoxaparin preoperatively.
    Pleym H, Videm V, Wahba A, Asberg A, Amundsen T, Bjella L, Dale O, Stenseth R.
    Eur J Cardiothorac Surg; 2006 Jun; 29(6):933-40. PubMed ID: 16675258
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Tranexamic acid and aprotinin in primary cardiac operations: an analysis of 220 cardiac surgical patients treated with tranexamic acid or aprotinin.
    Dietrich W, Spannagl M, Boehm J, Hauner K, Braun S, Schuster T, Busley R.
    Anesth Analg; 2008 Nov; 107(5):1469-78. PubMed ID: 18931201
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. In vitro effects of aprotinin on activated clotting time measured with different activators.
    Wang JS, Lin CY, Hung WT, Thisted RA, Karp RB.
    J Thorac Cardiovasc Surg; 1992 Oct; 104(4):1135-40. PubMed ID: 1383640
    [Abstract] [Full Text] [Related]

  • 13. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ, Joist JH, Hogue CW, Alsoufiev A, Kater K, Goodnough LT, Santoro SA, Spitznagel E, Rosenblum M, Lappas DG.
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
    [Abstract] [Full Text] [Related]

  • 14. Monitoring activated clotting time for combined heparin and aprotinin application: in vivo evaluation of a new aprotinin-insensitive test using Sonoclot.
    Ganter MT, Monn A, Tavakoli R, Genoni M, Klaghofer R, Furrer L, Honegger H, Hofer CK.
    Eur J Cardiothorac Surg; 2006 Aug; 30(2):278-84. PubMed ID: 16828293
    [Abstract] [Full Text] [Related]

  • 15. Alternative perioperative anticoagulation monitoring during cardiopulmonary bypass in aprotinin-treated patients.
    Huyzen RJ, Harder MP, Huet RC, Boonstra PW, Brenken U, van Oeveren W.
    J Cardiothorac Vasc Anesth; 1994 Apr; 8(2):153-6. PubMed ID: 7515704
    [Abstract] [Full Text] [Related]

  • 16. Is reduced systemic heparinization justified with heparin-bonded bypass circuits in cardiac surgery?--Experience with and without aprotinin.
    Kipfer B, Englberger L, Gygax E, Nydegger U, Carrel T.
    Transfus Apher Sci; 2003 Aug; 29(1):17-24. PubMed ID: 12877888
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. In vitro effect of hemodilution on activated clotting time and high-dose thrombin time during cardiopulmonary bypass.
    Huyzen RJ, van Oeveren W, Wei F, Stellingwerf P, Boonstra PW, Gu YJ.
    Ann Thorac Surg; 1996 Aug; 62(2):533-7. PubMed ID: 8694618
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.